ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line ...
WILMINGTON, Del.--(BUSINESS WIRE)--Sep 13, 2026-- Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically …